EML4-ALK positive lung cancer

Lung Cancer Research Foundation and ALK Positive Announce New Research Partnership

Retrieved on: 
Thursday, June 15, 2023

NEW YORK, June 15, 2023 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) and the ALK Positive Inc. (ALK Positive) announce the expansion of its current research partnership to fund $2 million in ALK-positive related lung cancer projects over three years. The aim of this research is to advance high-impact research focused upon transforming care and improving outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC).

Key Points: 
  • NEW YORK, June 15, 2023 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) and the ALK Positive Inc. (ALK Positive) announce the expansion of its current research partnership to fund $2 million in ALK-positive related lung cancer projects over three years.
  • The aim of this research is to advance high-impact research focused upon transforming care and improving outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC).
  • ALK positive lung cancers are seen in half of lung cancers diagnosed before age 50, nearly one third diagnosed before 40, and occurs in patients in their teens and twenties.
  • Both LCRF and ALK Positive are committed to investing in research that will improve therapeutic options and increase survivorship."

Lung Cancer Research Foundation and ALK Positive Announce Research Grant Awards

Retrieved on: 
Thursday, December 22, 2022

NEW YORK, Dec. 22, 2022 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) and ALK Positive Inc. (ALK Positive) announce funding of two ALK-positive related lung cancer projects. These grants, totaling $500,000, are awarded to researchers whose projects are focused upon transforming care and improving outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC).

Key Points: 
  • NEW YORK, Dec. 22, 2022 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) and ALK Positive Inc. (ALK Positive) announce funding of two ALK-positive related lung cancer projects.
  • The 2022 ALK Positive/Lung Cancer Research Award recipients include:
    The Lung Cancer Research Foundation® (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer.
  • LCRF's mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer.
  • ALK Positive is affiliated with the ALK Positive Support Group, the world's largest community of ALK-positive patients.

Lung Cancer Research Foundation Announces 2022 Scientific Research Grant Awards

Retrieved on: 
Tuesday, December 6, 2022

NEW YORK, Dec. 6, 2022 /PRNewswire/ -- The Lung Cancer Research Foundation® (LCRF) is pleased to announce the awardees of its 2022 Scientific Grant Program. This years' grant cycle includes three new areas of funding in addition to its Pilot grants: LCRF Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer, LCRF Research Grants on Oncogenic Drivers in Lung Cancer, and the newly launched LCRF Minority Career Development Award (CDA) for Lung Cancer. In partnership with ALK Positive, a separate request for proposals was introduced for the 2022 funding cycle.

Key Points: 
  • NEW YORK, Dec. 6, 2022 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) is pleased to announce the awardees of its 2022 Scientific Grant Program.
  • This years' grant cycle includes three new areas of funding in addition to its Pilot grants: LCRF Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer, LCRF Research Grants on Oncogenic Drivers in Lung Cancer, and the newly launched LCRF Minority Career Development Award (CDA) for Lung Cancer.
  • "I am honored to receive the William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation," said Dr. Cocco.
  • LCRF 2022 Grant Award Recipients:
    The 2022 Pilot Grant Program award recipients include:
    The 2022 Minority Career Development Award recipients include:
    The 2022 Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer award recipients include:
    The 2022 Research Grants on Oncogenic Drivers in Lung Cancer award recipients include:
    Swarnali Acharyya, PhD EGFR Resisters grant and James B. Dougherty Award recipient
    Drugging the S100A9-Retinoic acid pathway: companion biomarker and therapy
    The Regents of the University of California, San Francisco
    Emiliano Cocco, PhD MET Crusaders grant and William C. Rippe Award recipient
    The 2022 ALK Positive/Lung Cancer Research Award recipients include:
    For more information about LCRF and the Scientific Grant Program, visit LCRF.org/Research.

ALK Positive and LUNGevity Foundation Announce Recipients of the 2022 ALK-Positive Research Awards

Retrieved on: 
Thursday, December 1, 2022

WASHINGTON, Dec. 1, 2022 /PRNewswire/ -- Patient organization ALK Positive, in partnership with LUNGevity Foundation, announced the 2022 recipients of the ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards. The grant monies, totaling $1.75 million, were raised by ALK Positive and represent patients with ALK-positive non-small cell lung cancer themselves directly influencing the direction and focus of the research that affects their lives. This year's awardees are the third cohort to receive these awards.

Key Points: 
  • To transform advanced ALK-positive lung cancer into a chronic or curable disease, ALK Positive to award $1.75 million through their research award program
    WASHINGTON, Dec. 1, 2022 /PRNewswire/ -- Patient organization ALK Positive, in partnership with LUNGevity Foundation, announced the 2022 recipients of the ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards.
  • The recipients of the 2022 ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards are:
    "We are thrilled to continue our partnership with ALK Positive through these impactful research awards," said Upal Basu-Roy, PhD, MPH, executive director of research at LUNGevity Foundation.
  • The three scientists selected for the 2022 ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards are international experts in the field.
  • ALK Positive has implemented multiple programs to improve care for ALK- positive cancer patients, and accelerate the development and availability of improved treatments.

LUNGevity Foundation's No One Missed Campaign Celebrates Second Year of #KnowYourBiomarker Storytelling Initiative to Drive Awareness of Comprehensive Biomarker Testing in Lung Cancer

Retrieved on: 
Tuesday, November 1, 2022

WASHINGTON, Nov. 1, 2022 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, today celebrates the second year of its #KnowYourBiomarker social media initiative as part of the No One Missed campaign aimed at driving awareness of comprehensive biomarker testing in non-small cell lung cancer (NSCLC).

Key Points: 
  • "Time and time again, we've heard stories from people living with lung cancer about the difference comprehensive biomarker testing has made for their treatment journey," said Andrea Ferris, president and CEO of LUNGevity Foundation.
  • Here are two examples of people living with lung cancer who shared their biomarker testing experiences as part of the #KnowYourBiomarker initiative.
  • This is a philosophy she applied when faced with a stage IV lung cancer diagnosis in 2018 at age 52.
  • LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer.

Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates

Retrieved on: 
Monday, August 8, 2022

Announced a definitive merger agreement with Bristol Myers Squibb to acquire Turning Point Therapeutics for $76.00 per share.

Key Points: 
  • Announced a definitive merger agreement with Bristol Myers Squibb to acquire Turning Point Therapeutics for $76.00 per share.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated to close during the third quarter of 2022.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
  • These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.

Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC

Retrieved on: 
Wednesday, July 27, 2022

The purpose of the pre-NDA meeting was to discuss the companys planned NDA for repotrectinib for the treatment of ROS1+ advanced NSCLC.

Key Points: 
  • The purpose of the pre-NDA meeting was to discuss the companys planned NDA for repotrectinib for the treatment of ROS1+ advanced NSCLC.
  • The unmet need in ROS1+ advanced NSCLC patients is significant, and we continue to believe that repotrectinib could offer a best-in-class profile for the treatment of these patients.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
  • Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, May 26, 2022

Dr. Countouriotis is scheduled to present a company overview in New York on June 8 at 11 a.m.

Key Points: 
  • Dr. Countouriotis is scheduled to present a company overview in New York on June 8 at 11 a.m.
  • ET and scheduled to participate in a fireside chat on June 14 in Rancho Palo Verdes, California at 1 p.m.
  • Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer

Retrieved on: 
Monday, May 16, 2022

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022.

Key Points: 
  • SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022.
  • Before Astellas, Steve spent 16 years at Johnson & Johnson in roles of increasing responsibility in the commercial organization.
  • I look forward to joining the Turning Point team at this important time, said Mr. Sabus.
  • These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.

Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates

Retrieved on: 
Tuesday, May 10, 2022

Turning Point projects its cash position is sufficient to fund current operations through the first half of 2024.

Key Points: 
  • Turning Point projects its cash position is sufficient to fund current operations through the first half of 2024.
  • Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
  • These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.